Today, Oppenheimer initiated coverage on ACST stock with an “outperform” rating and a price target of $6. Even after today’s significant price increase, the price target still represents upside of ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Acasti Pharma (ACST) one of those stocks right now? Let's take a closer look at ...

Pharmaceutical company Acasti Pharma (NASDAQ:ACST) has a particular focus on developing drugs to help manage cardio-metabolic disorders. Traders might be interested in ACST stock if they like cheap ...

Acasti Pharma (NASDAQ:ACST) is a classic example of the extreme volatility of small-cap biotech stocks. It was only in late December that the shares were fetching $2.87, up from $1 a year earlier. But ...

The average one-year price target for Acasti Pharma (NasdaqCM:ACST) has been revised to 6.12 / share. This is an increase of 200.00% from the prior estimate of 2.04 dated July 5, 2023. The price ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Acasti Pharma (NASDAQ:ACST) just reported results for the first quarter of 2025. Acasti Pharma reported earnings per share of -24 cents. This was above the analyst estimate for EPS of -25 cents. The ...